Preclinical study failures rarely come from one dramatic mistake. More often, they come from small planning gaps that compound: an objective that is too broad, a model that does not fit the use case, endpoints that do not support the claim, or documentation that is not strong enough for later review.
Mistake 1: Starting with the protocol instead of the question
A protocol is not the strategy. Before drafting procedures, the team should agree on the product question, the decision the data will support, and the risks being evaluated. Without that alignment, the protocol may look complete but still fail to produce useful evidence.
Better approach: Write the study objective in one plain-language sentence before building the protocol.
Mistake 2: Choosing endpoints that are easy, not meaningful
Easy-to-collect data is not automatically valuable. Strong endpoints are tied to device performance, safety risks, tissue response, handling, healing, degradation, or another relevant development question.
Better approach: For each endpoint, ask: what decision will this help us make?
Mistake 3: Treating model selection as a default choice
Default models can be risky. A model should be justified based on anatomy, physiology, procedure, exposure, endpoint fit, and regulatory relevance. When the model has limitations, the study plan should explain those limitations and avoid overclaiming what the data can show.
Better approach: Document both why the model was selected and what it cannot answer.
Mistake 4: Waiting too long to consider GLP and reporting needs
GLP expectations, facility qualifications, raw data practices, quality assurance, deviation handling, and final report structure should be considered before study initiation. These details affect how credible and submission-ready the data will be. Waiting until the report stage can expose gaps that are difficult or impossible to fix.
Better approach: Decide early whether the study is exploratory, feasibility-focused, or intended to support a regulatory submission.
Mistake 5: Underestimating test article readiness
A study can be well designed and still compromised by device readiness issues. Confirm final design status, lot traceability, sterilization, packaging, labeling, shipping conditions, shelf life, accessory compatibility, and instructions for use before the study starts. If the tested device differs from the final device, the team should understand how that difference will be justified.
Better approach: Hold a test article readiness review before scheduling the study.
Mistake 6: Not planning the data story
The final output is not just a table of results. It is a data story that should connect objective, model, methods, observations, endpoints, deviations, pathology, interpretation, and limitations. Planning that story early makes the final report stronger and reduces the risk of confusing or fragmented conclusions.
Better approach: Outline the final report structure before the study begins.
Better studies start with better questions
Avoiding preclinical planning mistakes is not about adding bureaucracy. It is about making sure the study produces evidence that is scientifically meaningful, ethically justified, operationally realistic, and useful for the next development step.
Need guidance on preclinical strategy, biological evaluation, or study planning? Contact TEM Biomed to discuss your development program.
